cutaneous leishmaniasis

Cutaneous leishmaniasis is endemic to many parts of the world.

The incidence rate of cutaneous leishmaniasis is estimated to be between 1-1.5 million cases a year.

It is also an unusual cause of cutaneous leishmaniasis.

It is associated with cutaneous leishmaniasis also called "oriental sore".

It can cause a disease called oriental sore which is a form of cutaneous leishmaniasis.

There are about 20 species of Leishmania that may cause cutaneous leishmaniasis.

The evidence for optimal treatment of cutaneous leishmaniasis is patchy.

Clinical trials in Colombia showed a high efficacy for cutaneous leishmaniasis.

In 2005, it received the first approval for cutaneous leishmaniasis in Colombia.

Topical treatment with cantharidin appears to have some effect in an animal model of cutaneous leishmaniasis.

Miltefosine (Impavido), is a new drug for visceral and cutaneous leishmaniasis.

Cutaneous leishmaniasis is the most common form of leishmaniasis.

Vectorborne disease: cutaneous leishmaniasis is a high risk in some locations (2005)

They usually only cause a nasty itchy bite, but can also carry a rare skin disorder called cutaneous leishmaniasis.

Cutaneous leishmaniasis has been occurring in American and Canadian troops coming back from Afghanistan.

The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis.

Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis.

L. infantum causes cutaneous leishmaniasis in southern France.

Miltefosine for new world cutaneous leishmaniasis.

Though a vaccine does not yet exist that can prevent cutaneous leishmaniasis, it is speculated that one will be developed in the near future.

Ameen M. Cutaneous leishmaniasis: therapeutic strategies and future directions.

Cutaneous leishmaniasis coinfection in AIDS patients: case report and literature review.

Diffuse cutaneous leishmaniasis produces widespread skin lesions which resemble leprosy, and is particularly difficult to treat.

A number of different treatments have yielded results of varying effectiveness in the treatment of L. major caused cutaneous leishmaniasis.

It is now registered in many countries and is the first orally administered breakthrough therapy for visceral and cutaneous leishmaniasis.